CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 13,160 enrolled
Drug / intervention
Clopidogrel Tabletsdrug
Likely dose
Clopidogrel Tablets 75 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04734028
NCT04734028N/ACompleted
CompareCT.gov

Platelet Function and genoType-Related Long-term progGosis in DES-treated Patients : A Consortium From Multi-centered Registries

Gyeongsang National University Hospital·observational·Posted Feb 2, 2021·Updated Mar 31, 2022

In Brief

An observational study evaluating Clopidogrel Tablets for Coronary Artery Disease and 3 related conditions. Completed, enrolled 13,160 participants across 1 site.

Detailed Summary

The PTRG-DES consortium is a coalition composed of multi-center, real-world registries including CAD patients treated with DES in South Korea. From 9 academic registries in Korea, a total of 13,160 patients were enrolled for this database between July 2003 and August 2018. The aim of the study was to investigate long-term prognostic implications of platelet function and genotypes after DES implantation for significant CAD in South Korea.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsCoronary Artery Disease, Clopidogrel, Poor Metabolism of, Platelet Dysfunction, Stent Thrombosis
CountriesSouth Korea
CollaboratorsKorean Society of Interventional Cardiology

Timeline

N/ACompletedFinished
2003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedFeb 2, 2021
Enrollment StartJul 9, 2003
Primary CompletionAug 7, 2018
Study CompletionJun 30, 2020
TodayJul 2, 2026
Enrollment to primary: 15.1 yearsPosted 5.4 years ago

Interventions

Clopidogrel Tabletsdrug

DES-treated patients were treated with clopidogrel 75 mg daily and aspirin 100 mg daily